CN115887748B - Medical functional dressing for inhibiting bacteria and promoting healing and preparation method thereof - Google Patents
Medical functional dressing for inhibiting bacteria and promoting healing and preparation method thereof Download PDFInfo
- Publication number
- CN115887748B CN115887748B CN202211592946.2A CN202211592946A CN115887748B CN 115887748 B CN115887748 B CN 115887748B CN 202211592946 A CN202211592946 A CN 202211592946A CN 115887748 B CN115887748 B CN 115887748B
- Authority
- CN
- China
- Prior art keywords
- percent
- erythrina
- peptide
- healing
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000035876 healing Effects 0.000 title claims abstract description 12
- 230000001737 promoting effect Effects 0.000 title claims abstract description 10
- 241000894006 Bacteria Species 0.000 title claims description 13
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 244000195896 dadap Species 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 28
- 229910021538 borax Inorganic materials 0.000 claims abstract description 25
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 25
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 25
- 108010039918 Polylysine Proteins 0.000 claims abstract description 24
- 239000005313 bioactive glass Substances 0.000 claims abstract description 24
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 22
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 22
- 229920002752 Konjac Polymers 0.000 claims abstract description 22
- 229940046240 glucomannan Drugs 0.000 claims abstract description 22
- 235000010485 konjac Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000011668 ascorbic acid Substances 0.000 claims description 16
- 235000010323 ascorbic acid Nutrition 0.000 claims description 16
- 229960005070 ascorbic acid Drugs 0.000 claims description 16
- 229940057995 liquid paraffin Drugs 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 229940099259 vaseline Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 9
- 230000003385 bacteriostatic effect Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108090000526 Papain Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 6
- 235000019834 papain Nutrition 0.000 claims description 6
- 229940055729 papain Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 108090000145 Bacillolysin Proteins 0.000 claims description 4
- 102000035092 Neutral proteases Human genes 0.000 claims description 4
- 108091005507 Neutral proteases Proteins 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 206010048038 Wound infection Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000193996 Streptococcus pyogenes Species 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001363490 Monilia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application discloses a medical functional dressing for bacteriostasis and healing promotion and a preparation method thereof, and the product comprises the following main components: 1 to 3 percent of bioactive glass, 1 to 5 percent of konjak glucomannan, 3 to 10 percent of erythrina peptide, 0.5 to 1.5 percent of sodium tetraborate and 3 to 7 percent of epsilon-polylysine. The functional dressing has good antibacterial and healing promoting effects, and bioactive glass, erythrina peptide, sodium tetraborate, epsilon-polylysine and the like in the dressing have antibacterial and anti-inflammatory effects, so that wound infection can be avoided, and wound healing is promoted. The preparation method of the product is simple and convenient, is easy to popularize and use, and can be used for industrialized production.
Description
Technical Field
The application relates to the technical field of medical instruments, in particular to a medical functional dressing for bacteriostasis and healing promotion and a preparation method thereof.
Background
Wound healing is one of the current research hotspots in the medical field. The most common material in wound healing care is a medical dressing. The medical dressing refers to a material for wound treatment and skin care, is a common medical appliance product, and can provide ideal environment for wound healing, inhibit bacteria, promote wound healing and relieve wound pain. Medical dressing falls into traditional dressing and modern novel dressing, and traditional dressing includes gauze and cotton ball etc. and these dressings can not provide moist environment for the wound, and cause mechanical injury and foreign matter reaction with the tissue adhesion easily, be difficult for removing and antibiotic activity is low. Modern novel dressing is mainly developed based on wet wound healing theory and comprises various types of alginate dressing, chitosan dressing, nano silver dressing and the like.
According to different purposes, modern novel dressings comprise a blood type dressing, a bacteriostatic dressing, an anti-inflammatory dressing and a tissue regeneration promoting dressing, and although the modern novel dressing can comprehensively exert various effects such as hemostasis and antibiosis along with the continuous improvement and development of products, the emphasis of the effects of various products is still different for different wound types and different stages of wound surfaces. The common antibacterial dressing products at present mainly comprise nano silver dressing, nano zinc oxide dressing, nano calcium fluoride dressing and the like, and the dressing can show certain antibacterial property on common bacteria such as escherichia coli, staphylococcus aureus and the like, but has limited prevention effect on fungal infection.
Disclosure of Invention
In view of the defects of the prior art, the application develops a novel functional dressing, which takes bioactive glass, konjak glucomannan, erythrina peptide, sodium tetraborate and epsilon-polylysine as main functional components, and aims to improve the antibacterial and healing-promoting capabilities of the dressing.
The scheme of the application comprises the following contents:
the medical functional dressing for inhibiting bacteria and promoting healing comprises the following components in percentage by mass: 1 to 3 percent of bioactive glass, 1 to 5 percent of konjak glucomannan, 3 to 10 percent of erythrina peptide, 0.5 to 1.5 percent of sodium tetraborate and 3 to 7 percent of epsilon-polylysine. The combination of the effective components such as erythrina peptide, sodium tetraborate and the like plays a role in inhibiting various bacteria and fungi.
Preferably, the dressing further comprises ascorbic acid, sodium chloride, liquid paraffin, vaseline and water.
Preferably, the antibacterial and healing promoting medical functional dressing comprises the following components in percentage by mass: 1 to 3 percent of bioactive glass, 1 to 5 percent of konjak glucomannan, 3 to 10 percent of erythrina peptide, 0.5 to 1.5 percent of sodium tetraborate, 3 to 7 percent of epsilon-polylysine, 0.3 to 1.0 percent of ascorbic acid, 0.5 to 2 percent of sodium chloride, 1 to 2 percent of liquid paraffin, 1 to 2 percent of vaseline and the balance of water. The formula not only has good antibacterial effect, but also has excellent performances such as water absorption, water content, water vapor transmittance and the like, and can more effectively promote wound healing.
Preferably, the antibacterial and healing promoting medical functional dressing comprises the following components in percentage by mass: 1% of bioactive glass, 2% of konjak glucomannan, 10% of erythrina peptide, 1% of sodium tetraborate, 7% of epsilon-polylysine, 0.3% -1.0% of ascorbic acid, 0.5% -2% of sodium chloride, 1% -2% of liquid paraffin, 1% -2% of vaseline and the balance of water.
Preferably, the erythrina peptide is prepared by:
mixing erythrina bark powder with water, regulating pH to 5.5-6.5, adding neutral proteinase and papain, enzymolyzing at 45-55 deg.c for 2-3 hr, inactivating enzyme, cooling, centrifuging, collecting supernatant, collecting component with molecular mass less than or equal to 2kDa, and freeze drying. The method can obtain the active antibacterial small peptide from erythrina.
Preferably, the addition amount of neutral protease and papain is 2% and 0.5% of the mass of the enzymolysis substrate.
Preferably, the erythrina bark powder to water ratio is 1g:25mL.
Preferably, the erythrina peptide has an amino acid sequence of VLEDEQEGLSVK. The small peptide has better antibacterial activity.
Preferably, the erythrina peptide is added in an amount of 10%.
On the other hand, the application specifically provides a preparation method of the antibacterial and healing promoting medical functional dressing, which comprises the following steps: dispersing konjak glucomannan, epsilon-polylysine, liquid paraffin and vaseline in water to obtain phase A; mixing bioactive glass, erythrina peptide, sodium tetraborate, ascorbic acid, sodium chloride and the balance of water to obtain phase B; slowly pouring the phase A into the phase B, and uniformly mixing at 35+/-5 ℃.
The beneficial effects obtained by the application are as follows:
(1) The functional dressing has good antibacterial and healing promoting effects, and bioactive glass, erythrina peptide, sodium tetraborate, epsilon-polylysine and the like in the dressing have antibacterial and anti-inflammatory effects, so that wound infection can be avoided, and wound healing is promoted.
(2) The functional dressing has good inhibition effect on bacteria such as escherichia coli and the like, and also has obvious inhibition effect on fungi such as candida albicans and the like.
(3) The erythrina peptide added by the application has good inhibition effect on fungi, and has wider antibacterial spectrum and better antibacterial effect when being matched with other antibacterial components.
(4) With the theory of moist wound healing, it is believed that wounds heal rapidly under conditions of appropriate moisture. The product has good antibacterial effect, and through reasonable preparation of the raw materials, the product has good water-containing characteristic, can keep the wound in a wet state, ensures that the wound maintains good gas exchange with the outside, and promotes the healing of the wound.
(5) The functional dressing can be used for nursing wound surfaces such as burns, scalds, sunburn, ulcers, bruises, cuts and the like and surrounding skin.
(6) The application can provide new choices for clinical caregivers.
(7) The preparation method of the product is simple and convenient, is easy to popularize and use, and can be used for industrialized production.
Detailed Description
In order to facilitate the understanding of the technical content of the present application, the present application will be described in further detail with reference to specific examples and experimental test results.
The bioactive glass, konjak glucomannan, sodium tetraborate, epsilon-polylysine, ascorbic acid, sodium chloride, liquid paraffin and Vaseline in the formula are all commercial products.
Antibacterial performance test (minimum inhibitory concentration test):
bacterial infection of wounds can trigger severe inflammatory reactions and thus delay wound healing, and thus antimicrobial properties are an important indicator for evaluating the quality of medical dressings. The main bacteria infecting wounds are staphylococcus aureus (Staphylococcus aureus), streptococcus pyogenes (Streptococcus pyogenes), escherichia coli (Escherichia coli) and pseudomonas aeruginosa (Pseudomonas aeruginosa), and the main fungus is candida albicans (Monilia albicans). The test analyzes the antibacterial performance of the product by testing the lowest antibacterial concentration of each sample on bacteria or fungi.
1.1 preparation of materials
(1) Neutral protease: CAS (CAS) 9068-59-1, and the enzyme activity is 5 ten thousand U/g; papain: CAS 9001-73-4, enzyme activity 10 ten thousand U/g.
(2) Preparation of erythrina peptide:
the flow is as follows: erythrina bark powder, adding water, regulating pH, carrying out enzymolysis, inactivating enzyme, cooling, centrifuging, taking supernatant, and carrying out ultrafiltration to keep the peptide fragment less than or equal to 2 kDa.
The method comprises the following specific steps: mixing erythrina bark powder with distilled water at a ratio of 1:25 (w/v, g/mL), regulating pH to 5.5 with NaOH or HCl, adding neutral protease and papain at an amount of 2% (w/w) and 0.5% (w/w), respectively, performing enzymolysis at 50deg.C for 2 hr, inactivating enzyme in 95deg.C water bath, cooling, centrifuging at 8000r/min for 20min, and collecting supernatant. Separating the supernatant with ultrafiltration membrane, collecting the fraction with molecular mass less than or equal to 2kDa, and freeze-drying.
(3) Preparing a sample to be tested:
on the basis of pre-experiments, the antibacterial effect is better when the product formula is 1% -3% of bioactive glass, 1% -5% of konjak glucomannan, 3% -10% of erythrina peptide, 0.5% -1.5% of sodium tetraborate, 3% -7% of epsilon-polylysine and the balance of water. The test results of a portion of the samples to be tested are provided below.
Sample 1 to be tested: according to the formula, 1% of bioactive glass, 2% of konjak glucomannan, 10% of erythrina peptide, 1% of sodium tetraborate, 7% of epsilon-polylysine and the balance of water are uniformly mixed.
Sample 2 to be tested: according to the formula, 1% of bioactive glass, 2% of konjak glucomannan, 1% of sodium tetraborate, 7% of epsilon-polylysine and the balance of water are uniformly mixed.
Sample 3 to be tested: 10% erythrina peptide aqueous solution.
Blank control: sterile water.
1.2 experimental procedure:
(1) Formulation 10 6 CFU/mL bacterial liquid, adding 100 mu L bacterial liquid into a 96-well plate;
(2) The products to be tested are prepared into different concentrations by water, 100 mu L is added into a 96-well plate, and the final concentrations of the products are respectively 50, 25, 12.5, 6.25 and 3.125mg/L.
(3) And (3) placing the 96-well plate in a 37 ℃ incubator for shake culture for 24 hours, and observing with naked eyes that no bacteria grows, namely the minimum inhibitory concentration MIC of the tested bacteria. If the naked eye is not judged well, reading the OD 625 The product concentration with the value, OD value less than 0.05, is MIC of the test bacteria.
1.3 experimental results:
TABLE 1
Note that: the results remained consistent throughout the three trials.
The minimum inhibitory concentration of each sample on staphylococcus aureus, streptococcus pyogenes, escherichia coli, pseudomonas aeruginosa and candida albicans can be known, and samples 1-2 show inhibition effect on the growth of staphylococcus aureus, streptococcus pyogenes, pseudomonas aeruginosa and candida albicans, and sample 3 has no inhibition effect on escherichia coli at the concentration lower than 50 mg/L. The MIC of the sample 1 to the candida albicans and the pseudomonas aeruginosa is 6.25mg/L, and the MIC to the staphylococcus aureus, the streptococcus pyogenes and the escherichia coli is 25mg/L, 12.5mg/L and 50mg/L respectively, and the antibacterial effect of the sample 1 is generally better than that of the samples 2 and 3. From the comparison between the samples, it was found that the combination of bioactive glass, konjak glucomannan, sodium tetraborate, epsilon-polylysine (i.e., sample 2) and erythrina peptide (sample 3) had an enhanced inhibitory effect on candida albicans, which may be related to the different mechanism of inhibition of fungi.
On the basis of the research of bacteriostasis performance, other properties, cost, convenience in use and the like of the product are comprehensively considered, and the application provides an optimal product formula. Functional dressing formula: 1 to 3 percent of bioactive glass, 1 to 5 percent of konjak glucomannan, 3 to 10 percent of erythrina peptide, 0.5 to 1.5 percent of sodium tetraborate, 3 to 7 percent of epsilon-polylysine, 0.3 to 1.0 percent of ascorbic acid, 0.5 to 2 percent of sodium chloride, 1 to 2 percent of liquid paraffin, 1 to 2 percent of vaseline and the balance of water.
The optimal preparation method of the product comprises the following steps:
dispersing konjac glucomannan, epsilon-polylysine, liquid paraffin and vaseline with a small amount of water to obtain phase A; mixing bioactive glass, erythrina peptide, sodium tetraborate, ascorbic acid, sodium chloride and the balance of water to obtain phase B; slowly pouring the phase A into the phase B, and uniformly mixing at 35+/-5 ℃.
Based on the current results of research, some specific examples are set forth herein.
Example 1
Functional dressing formula: 1% of bioactive glass, 5% of konjak glucomannan, 5% of erythrina peptide, 1.5% of sodium tetraborate, 5% of epsilon-polylysine, 1.0% of ascorbic acid, 1% of sodium chloride, 1% of liquid paraffin, 2% of vaseline and the balance of water.
Example 2
Functional dressing formula: 1% bioactive glass, 1% konjak glucomannan, 10% erythrina peptide, 1% sodium tetraborate, 7% epsilon-polylysine, 1.0% ascorbic acid, 1% sodium chloride, 1% liquid paraffin, 1% vaseline and the balance water.
Example 3
Functional dressing formula: 3% of bioactive glass, 5% of konjak glucomannan, 3% of erythrina peptide, 1.5% of sodium tetraborate, 3% of epsilon-polylysine, 1.0% of ascorbic acid, 1% of sodium chloride, 2% of liquid paraffin, 1% of vaseline and the balance of water.
Example 4
Functional dressing formula: 1% of bioactive glass, 5% of konjak glucomannan, 10% of erythrina peptide, 0.5% of sodium tetraborate, 7% of epsilon-polylysine, 0.3% of ascorbic acid, 2% of sodium chloride, 2% of liquid paraffin, 1% of vaseline and the balance of water.
Example 5
Functional dressing formula: 1% bioactive glass, 2% konjak glucomannan, 10% erythrina peptide, 1% sodium tetraborate, 7% epsilon-polylysine, 0.3% ascorbic acid, 2% sodium chloride, 2% liquid paraffin, 1% vaseline and the balance water.
Other achievements:
through further screening analysis on erythrina peptide, a plurality of antibacterial peptides which exert good antibacterial effect in wet dressing products are preliminarily determined, and through analysis and screening, the antibacterial peptide with obvious antibacterial effect is obtained. The amino acid sequence of the antibacterial peptide is as follows: VLEDEQEGLSVK. The MIC value was measured by using the bacteriostatic small peptide, and the results are shown in Table 2. The result shows that the antibacterial small peptide has good antibacterial property and can be used in functional dressing.
TABLE 2
The product of the application has good performances such as water absorption, water content, water vapor transmittance and the like, and has no other safety problems.
The above-mentioned embodiments are only some of the preferred embodiments of the present application, and are not intended to limit the present application, but the scope of the present application is not limited to the above-mentioned embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (8)
1. The medical functional dressing for inhibiting bacteria and promoting healing is characterized by comprising the following components in percentage by mass: 1 to 3 percent of bioactive glass, 1 to 5 percent of konjak glucomannan, 3 to 10 percent of erythrina peptide, 0.5 to 1.5 percent of sodium tetraborate and 3 to 7 percent of epsilon-polylysine;
the amino acid sequence of the erythrina peptide is VLEDEQEGLSVK, or the erythrina peptide is prepared by the following steps: mixing erythrina bark powder with water, regulating pH to 5.5-6.5, adding neutral proteinase and papain, enzymolyzing at 45-55 deg.c for 2-3 hr, inactivating enzyme, cooling, centrifuging, collecting supernatant, collecting component with molecular mass less than or equal to 2kDa, and freeze drying.
2. The bacteriostatic, healing-promoting medical functional dressing according to claim 1, wherein the dressing further comprises ascorbic acid, sodium chloride, liquid paraffin, vaseline and water.
3. The bacteriostatic, healing-promoting medical functional dressing according to claim 1, characterized by comprising the following components in percentage by mass: 1 to 3 percent of bioactive glass, 1 to 5 percent of konjak glucomannan, 3 to 10 percent of erythrina peptide, 0.5 to 1.5 percent of sodium tetraborate, 3 to 7 percent of epsilon-polylysine, 0.3 to 1.0 percent of ascorbic acid, 0.5 to 2 percent of sodium chloride, 1 to 2 percent of liquid paraffin, 1 to 2 percent of vaseline and the balance of water.
4. The bacteriostatic, healing-promoting medical functional dressing according to claim 1, characterized by comprising the following components in percentage by mass: 1% of bioactive glass, 2% of konjak glucomannan, 10% of erythrina peptide, 1% of sodium tetraborate, 7% of epsilon-polylysine, 0.3% -1.0% of ascorbic acid, 0.5% -2% of sodium chloride, 1% -2% of liquid paraffin, 1% -2% of vaseline and the balance of water.
5. The bacteriostatic, healing-promoting medical functional dressing according to claim 4, wherein the addition amount of neutral protease and papain is 2% and 0.5% of the mass of the enzymatic substrate.
6. The bacteriostatic, healing-promoting medical functional dressing according to claim 5, wherein the ratio of erythrina bark powder to water is 1g:25mL.
7. The bacteriostatic, healing-promoting medical functional dressing according to claim 1, wherein the erythrina peptide is added in an amount of 10%.
8. The method for preparing the antibacterial and healing-promoting medical functional dressing according to any one of claims 2 to 6, which is characterized by comprising the following steps: dispersing konjak glucomannan, epsilon-polylysine, liquid paraffin and vaseline in water to obtain phase A; mixing bioactive glass, erythrina peptide, sodium tetraborate, ascorbic acid, sodium chloride and the balance of water to obtain phase B; slowly pouring the phase A into the phase B, and uniformly mixing at 35+/-5 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211592946.2A CN115887748B (en) | 2022-12-13 | 2022-12-13 | Medical functional dressing for inhibiting bacteria and promoting healing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211592946.2A CN115887748B (en) | 2022-12-13 | 2022-12-13 | Medical functional dressing for inhibiting bacteria and promoting healing and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115887748A CN115887748A (en) | 2023-04-04 |
| CN115887748B true CN115887748B (en) | 2023-09-01 |
Family
ID=86493110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211592946.2A Active CN115887748B (en) | 2022-12-13 | 2022-12-13 | Medical functional dressing for inhibiting bacteria and promoting healing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115887748B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105536040A (en) * | 2015-12-30 | 2016-05-04 | 天津嘉氏堂科技有限公司 | Dressing for chronic wound |
| CN107185026A (en) * | 2017-05-15 | 2017-09-22 | 陕西科技大学 | A kind of preparation method of konjaku glucomannan medical antibacterial dressing |
| CN107693833A (en) * | 2017-10-18 | 2018-02-16 | 张家港蓝智生物科技有限公司 | A kind of dispel scar moist dressing and preparation method containing bioactivity glass |
| CN108066805A (en) * | 2016-11-17 | 2018-05-25 | 中国科学院大连化学物理研究所 | A kind of bionical bacteriostatic film of epsilon-polylysine and its preparation and application |
| KR20190042151A (en) * | 2017-10-16 | 2019-04-24 | (주)예스킨 | Anti-fungal composition derived from natural products |
| CN112851951A (en) * | 2021-01-14 | 2021-05-28 | 中国科学院理化技术研究所 | Dialdehyde chitosan grafted with epsilon-polylysine and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10316156B3 (en) * | 2003-04-09 | 2004-10-14 | Beiersdorf Ag | Antimicrobial polymer materials and their use as a wound dressing |
-
2022
- 2022-12-13 CN CN202211592946.2A patent/CN115887748B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105536040A (en) * | 2015-12-30 | 2016-05-04 | 天津嘉氏堂科技有限公司 | Dressing for chronic wound |
| CN108066805A (en) * | 2016-11-17 | 2018-05-25 | 中国科学院大连化学物理研究所 | A kind of bionical bacteriostatic film of epsilon-polylysine and its preparation and application |
| CN107185026A (en) * | 2017-05-15 | 2017-09-22 | 陕西科技大学 | A kind of preparation method of konjaku glucomannan medical antibacterial dressing |
| KR20190042151A (en) * | 2017-10-16 | 2019-04-24 | (주)예스킨 | Anti-fungal composition derived from natural products |
| CN107693833A (en) * | 2017-10-18 | 2018-02-16 | 张家港蓝智生物科技有限公司 | A kind of dispel scar moist dressing and preparation method containing bioactivity glass |
| CN112851951A (en) * | 2021-01-14 | 2021-05-28 | 中国科学院理化技术研究所 | Dialdehyde chitosan grafted with epsilon-polylysine and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 食源性生物活性肽的功能及其在食品中的应用;李福荣;赵爽;张秋;尹淑涛;;食品研究与开发(第20期);210-217 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115887748A (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Younis et al. | Silver nanoparticles green synthesis via cyanobacterium Phormidium sp.: characterization, wound healing, antioxidant, antibacterial, and anti-inflammatory activities. | |
| Molan | Honey as a topical antibacterial agent for treatment of infected wounds | |
| Makhayeva et al. | Polymeric iodophors: preparation, properties, and biomedical applications | |
| Alam et al. | Honey: a potential therapeutic agent for managing diabetic wounds | |
| Archana et al. | In vivo evaluation of chitosan–PVP–titanium dioxide nanocomposite as wound dressing material | |
| Pieper | Honey-based dressings and wound care: an option for care in the United States | |
| CN102492182B (en) | Biofilms of rare-earth element contained chitosan and/or derivatives of chitosan | |
| WO2010079209A2 (en) | Compositions for treating wounds and skin conditions | |
| Parwani et al. | Evaluation of Moringa oleifera seed biopolymer-PVA composite hydrogel in wound healing dressing | |
| White | Flaminal®: a novel approach to wound bioburden control | |
| Zuo et al. | Preparation and characterization of tannin-maltodextrin-polyvinyl alcohol hydrogel based on hydrogen bonding for wound healing | |
| CN113679881A (en) | Medical dressing with antibacterial property and preparation method thereof | |
| CN106344954A (en) | Bio-antimicrobial bacterial cellulose dressing and preparation method thereof | |
| CN113018499A (en) | Preparation method of ozone oil-water gel composite application capable of sterilizing, resisting virus and absorbing moisture | |
| CN115887748B (en) | Medical functional dressing for inhibiting bacteria and promoting healing and preparation method thereof | |
| CN114456239B (en) | Lithospermum and external antibacterial peptide gel preparation prepared from same and application | |
| Samancıoğlu et al. | A new dressing material in diabetic wounds: Wound healing activity of oleuropein-rich olive leaf extract in diabetic rats | |
| CN111518187B (en) | Antibacterial peptide DN6NH2 and application thereof | |
| US20240277894A1 (en) | Composite antibacterial hydrogel dressing, preparation method and application thereof | |
| Huang et al. | Shiunko promotes epithelization of wounded skin | |
| CN113440645A (en) | Composite lysozyme liquid dressing for wound surface and preparation method thereof | |
| US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
| KR20210053779A (en) | Hydrogel comprising Mushroom-derived Chitosan or derivatives thereof and Manufacturing Method thereof | |
| CN114225100A (en) | Porphyridium-based liquid dressing and preparation method thereof | |
| CN109010907B (en) | A kind of functionality Wound-protection liquid body dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |